Legacy Capital Partners’s Biogen BIIB Stock Holding History

Legacy Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-878	Closed	-$246K	–	141
2021 Q1	$246K	Hold	878	–	–	0.09%	125
2020 Q4	$215K	Buy	878 +50	+6%	+$12.9K	0.08%	128
2020 Q3	$235K	Hold	828	–	–	0.1%	125
2020 Q2	$222K	Hold	828	–	–	0.1%	131
2020 Q1	$262K	Buy	828 +50	+6%	+$15.2K	0.13%	111
2019 Q4	$231K	Buy	+778	New	+$216K	0.09%	139
2016 Q2	–	Sell	-790	Closed	-$206K	–	113
2016 Q1	$206K	Sell	790 -875	-53%	-$231K	0.13%	107
2015 Q4	$511K	Sell	1,665 -665	-29%	-$191K	0.33%	73
2015 Q3	$680K	Buy	2,330 +50	+2%	+$16.5K	0.46%	63
2015 Q2	$921K	Buy	2,280 +75	+3%	+$30.1K	0.6%	58
2015 Q1	$932K	Hold	2,205	–	–	0.59%	60
2014 Q4	$749K	Buy	+2,205	New	+$713K	0.48%	61

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Legacy Capital Partners's BIIB Position: Q2 2021 in Review

Legacy Capital Partners sold out of Biogen (BIIB) in Q2 2021, closing a stake of 878 shares — an estimated $246K sold.

Legacy Capital Partners first reported a position in BIIB in Q4 2014 and held it in 12 quarters. The position peaked at $932K in Q1 2015. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Legacy Capital Partners reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Legacy Capital Partners sold 878 Biogen shares in Q2 2021, an estimated $246K.
Legacy Capital Partners first reported a position in Biogen in Q4 2014 and held it in 12 quarters.
Legacy Capital Partners's Biogen position peaked at $932K in Q1 2015.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Legacy Capital Partners's 13F filing for Q2 2021, filed 13 Jul 2021.